KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Cash & Equivalents (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Cash & Equivalents for 18 consecutive years, with $3.0 billion as the latest value for Q1 2026.

  • For Q1 2026, Cash & Equivalents fell 4.13% year-over-year to $3.0 billion; the TTM value through Mar 2026 reached $3.0 billion, down 4.13%, while the annual FY2025 figure was $3.1 billion, 25.32% up from the prior year.
  • Cash & Equivalents hit $3.0 billion in Q1 2026 for Regeneron Pharmaceuticals, down from $3.1 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $3.9 billion in Q1 2023 and bottomed at $1.9 billion in Q2 2024.
  • Average Cash & Equivalents over 5 years is $2.8 billion, with a median of $2.7 billion recorded in 2023.
  • Year-over-year, Cash & Equivalents skyrocketed 132.68% in 2022 and then crashed 42.94% in 2023.
  • Regeneron Pharmaceuticals' Cash & Equivalents stood at $3.1 billion in 2022, then dropped by 12.1% to $2.7 billion in 2023, then decreased by 8.86% to $2.5 billion in 2024, then rose by 25.32% to $3.1 billion in 2025, then decreased by 4.99% to $3.0 billion in 2026.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $3.0 billion, $3.1 billion, and $2.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.